<DOC>
	<DOCNO>NCT00464165</DOCNO>
	<brief_summary>The primary objective ass efficacy 2 fixed dos rimonabant versus placebo abstinence tobacco use cigarette smoker . The secondary objective evaluate effect rimonabant crave weight clinical biological safety tolerability rimonabant population cigarette tobacco smoker 10-week treatment period observe percentage abstinent subject 40-week follow-up post treatment .</brief_summary>
	<brief_title>Comparison Efficacy Safety Rimonabant 5mg/Day 20mg/Day Versus Placebo Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Smokers smoke least 10 cigarettes/day mean within 2 month precede screen visit Motivated quit score great equal 6 tenpoint Motivation Scale Non tobacco cigarettes consumption Chronic use marijuana Pregnancy , breastfeed Any clinically significant disease might interfere efficacy safety evaluation study drug Concomitant use drug aid smoke cessation might induce weight change</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>abstinence</keyword>
</DOC>